Results 101 to 110 of about 26,318 (221)

Performance Characteristics of Anti–Collagen II Antibodies in Relapsing Polychondritis and Related Diseases: Prospective Analysis, Systematic Review, and Meta‐Analysis

open access: yesArthritis Care &Research, Volume 78, Issue 6, Page 798-809, June 2026.
Objective Relapsing polychondritis (RP) is a rare disease defined by recurrent cartilaginous inflammation. Anti–collagen II (Col2) antibodies have been proposed as a diagnostic biomarker for RP, but their performance characteristics are not well defined.
Karyssa Stonick   +6 more
wiley   +1 more source

Molecular Regulation of Bone Turnover in Juvenile Idiopathic Arthritis: Animal Models, Cellular Features and TNFα

open access: yesFrontiers in Bioscience-Landmark
We review the abnormal bone turnover that is the basis of idiopathic inflammatory or rheumatoid arthritis and bone loss, with emphasis on Tumor Necrosis Factor-alpha (TNFα)-related mechanisms.
Harry C Blair   +8 more
doaj   +1 more source

Disease Remission: A Scoping Review With Thematic Analysis of the Scientific Literature With Implications for Chronic Rhinosinusitis

open access: yesInternational Forum of Allergy &Rhinology, Volume 16, Issue 6, Page 615-629, June 2026.
ABSTRACT Background Remission, a term used to describe a goal of treatment for some chronic diseases, has recently been proposed for chronic rhinosinusitis (CRS). However, it is unclear what remission means for CRS and why it should serve as a goal in the present‐day treatment of CRS.
Nikhil Parail   +7 more
wiley   +1 more source

Single‐Cell RNA Sequencing Informs Precision Targeting of Monogenic Lupus Associated With IKZF1 Haploinsufficiency

open access: yesArthritis &Rheumatology, Volume 78, Issue 6, Page 1231-1244, June 2026.
Objective This study aimed to investigate the mechanisms of immune dysregulation in a pediatric patient with monogenic lupus driven by IKZF1 haploinsufficiency. Methods Peripheral immune cells from a patient with IKZF1 haploinsufficiency, patients with lupus with no currently known genetic mutations, and healthy controls were analyzed using single‐cell
Qi Zheng   +6 more
wiley   +1 more source

Interleukin‐18 Levels Are Associated With Disease Course in Patients With Still Disease Treated With Interleukin‐1 Inhibitors

open access: yesArthritis &Rheumatology, Volume 78, Issue 6, Page 1327-1338, June 2026.
Objective To evaluate the prognostic utility of circulating interleukin‐18 (IL‐18) levels in predicting disease activity, macrophage activation syndrome (MAS), and disease course in patients with Still disease (SD) receiving first‐line IL‐1 inhibitors (IL‐1i).
Matteo Trevisan   +8 more
wiley   +1 more source

Acute Disseminated Encephalomyelitis Presenting as Fever of Unknown Origin in a 4‐Year‐Old Boy: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT A 4‐year‐old boy presented with prolonged fever of unknown origin and systemic inflammation without early neurological signs. MRI revealed multifocal demyelination, and MOG antibodies were positive. He was diagnosed with ADEM and treated with steroids and IVIg, but relapsed twice, consistent with multiphasic disseminated encephalomyelitis ...
Pedro Pau
wiley   +1 more source

Tacrolimus as Single‐Agent Immunotherapy for Adult‐Onset Myasthenia Gravis: Remission, Relapse, and Safety

open access: yesCNS Neuroscience &Therapeutics, Volume 32, Issue 6, June 2026.
Tacrolimus monotherapy yields high remission in adult‐onset MG, especially in new‐onset or younger patients. Relapse is linked to low tacrolimus concentration and rapid tapering. Hyperglycemia was the most common ADR. Long‐term use may increase cancer risk.
Zhangyan Geng   +16 more
wiley   +1 more source

Serious Infection in Crohn's Disease Patients Treated With Ustekinumab: US Food and Drug Administration Active Postmarket Risk Identification and Analysis in the Sentinel Initiative

open access: yesClinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1514-1521, June 2026.
The U.S. Food and Drug Administration (FDA) used an Active Postmarket Risk Identification and Analysis (ARIA) system to address a safety issue (serious infection) identified during clinical review of an application to market ustekinumab as a treatment for Crohn's disease (CD). FDA used an active‐comparator new‐user cohort design, data from six Sentinel
Joel L. Weissfeld   +9 more
wiley   +1 more source

Tocilizumab and Dexamethasone Reduce TNF‐α and IL‐33 and Oxidative Stress in Kidney Tissue in Oleic Acid‐Induced ARDS Model

open access: yesJournal of Biochemical and Molecular Toxicology, Volume 40, Issue 6, June 2026.
Oleic acid causes ARDS‐associated AKI. Tocilizumab and dexamethasone reduces ARDS‐induced kidney injury. The width of the filtration slits increases in kidney injury. Tocilizumab and dexamethasone suppress TNF‐a and IL‐33. ABSTRACT The most common extrapulmonary organ injury in cases of acute respiratory distress syndrome (ARDS) is acute kidney injury (
Huseyin Serkan Erol   +4 more
wiley   +1 more source

Analysis of juvenile idiopathic arthritis associated uveitis in India over the last 16 years

open access: yesIndian Journal of Ophthalmology, 2007
Aim: Juvenile idiopathic arthritis (JIA) associated uveitis is one of the most common causes of visual morbidity in children. We report the systemic, clinical and investigational features of a cohort of all cases of JIA associated uveitis seen at our ...
Sudharshan S   +2 more
doaj  

Home - About - Disclaimer - Privacy